Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silexion Therapeutics Corp - Ordinary Shares (NQ:SLXN)

0.7217 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silexion Therapeutics Corp - Ordinary Shares

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit 
Via News Direct
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Silexion Investigational Pancreatic Cancer Treatment Shows Promise In Animal Studies
Silexion Therapeutics' stock surged after the company revealed preclinical findings for SIL-204, its siRNA candidate. 
Via Benzinga
Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204
New data from preclinical studies for SIL-204 seems to have sparked the markets attention for Silexion Therapeutics. 
Via News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Silexion Therapeutics Unveils Promising Preclinical Data for SIL-204 Just Days After New LODER Data: Advancing the Fight Against Pancreatic Cancer
Via AB Newswire
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
From Silexion Therapeutics Corp.
Via Business Wire
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
Silexion Therapeutics sees surge in trading volume after revealing new findings from a Phase 2 trial of LODER in pancreatic cancer patients. 
Via Benzinga
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment
Via AB Newswire
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
From Silexion Therapeutics
Via Business Wire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Via AB Newswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge. 
Via News Direct
Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
From PESG Research
Via Business Wire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback